CN1113669C - 治疗内皮创伤的方法 - Google Patents

治疗内皮创伤的方法 Download PDF

Info

Publication number
CN1113669C
CN1113669C CN97199338A CN97199338A CN1113669C CN 1113669 C CN1113669 C CN 1113669C CN 97199338 A CN97199338 A CN 97199338A CN 97199338 A CN97199338 A CN 97199338A CN 1113669 C CN1113669 C CN 1113669C
Authority
CN
China
Prior art keywords
epo
endothelial
cisplatin
cells
chemotherapeutic agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN97199338A
Other languages
English (en)
Chinese (zh)
Other versions
CN1235512A (zh
Inventor
阿塔纳修斯A·阿纳诺斯托
乔治·西高纳斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
East Carolina University
Original Assignee
East Carolina University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24861777&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN1113669(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by East Carolina University filed Critical East Carolina University
Publication of CN1235512A publication Critical patent/CN1235512A/zh
Application granted granted Critical
Publication of CN1113669C publication Critical patent/CN1113669C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Materials For Medical Uses (AREA)
  • External Artificial Organs (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN97199338A 1996-09-11 1997-09-10 治疗内皮创伤的方法 Expired - Fee Related CN1113669C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/712,358 US20020052309A1 (en) 1996-09-11 1996-09-11 Method of treating endothelial injury
US08/712,358 1996-09-11

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CNB021506884A Division CN1250281C (zh) 1996-09-11 2002-11-12 治疗内皮创伤的方法

Publications (2)

Publication Number Publication Date
CN1235512A CN1235512A (zh) 1999-11-17
CN1113669C true CN1113669C (zh) 2003-07-09

Family

ID=24861777

Family Applications (2)

Application Number Title Priority Date Filing Date
CN97199338A Expired - Fee Related CN1113669C (zh) 1996-09-11 1997-09-10 治疗内皮创伤的方法
CNB021506884A Expired - Fee Related CN1250281C (zh) 1996-09-11 2002-11-12 治疗内皮创伤的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CNB021506884A Expired - Fee Related CN1250281C (zh) 1996-09-11 2002-11-12 治疗内皮创伤的方法

Country Status (11)

Country Link
US (5) US20020052309A1 (enExample)
EP (1) EP0933995B8 (enExample)
JP (3) JP2001503028A (enExample)
CN (2) CN1113669C (enExample)
AT (1) ATE282425T1 (enExample)
CA (1) CA2265547C (enExample)
DE (1) DE69731652T2 (enExample)
DK (1) DK0933995T3 (enExample)
ES (1) ES2231889T3 (enExample)
PT (1) PT933995E (enExample)
WO (1) WO1998010650A1 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2686899B1 (fr) * 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
IL124015A0 (en) 1998-04-08 1999-01-26 Yeda Res & Dev Pharmaceutical compositions comprising a protein
FR2786104B1 (fr) * 1998-11-25 2002-12-27 Centre Nat Rech Scient Inhibiteurs de l'activation de nf-kb, et leurs utilisations pharmaceutiques
PL352223A1 (en) * 1999-04-13 2003-08-11 Kenneth S Warren Inst Modulation of excitable tissue function by peripherally administered erythropoietin
US7309687B1 (en) * 1999-04-13 2007-12-18 The Kenneth S. Warren Institute, Inc. Methods for treatment and prevention of neuromuscular and muscular conditions by peripherally administered erythropoietin
US7345019B1 (en) * 1999-04-13 2008-03-18 The Kenneth S. Warren Institute, Inc. Modulation of excitable tissue function by peripherally administered erythropoietin
US6171620B1 (en) * 1999-04-27 2001-01-09 Health Research, Inc. Method of enhancing the efficacy of anti-tumor agents
CA2372782A1 (en) * 1999-05-11 2000-11-16 Wing Cheung Pharmacokinetic and pharmacodynamic modeling of erythropoietin administration
US20030152562A1 (en) * 2001-10-23 2003-08-14 Yissum Research Development Company Of The Hebrew University Of Jerusalem Vitro micro-organs, and uses related thereto
EP1229934B1 (en) 1999-10-01 2014-03-05 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
CA2405550A1 (en) 2000-04-12 2001-10-25 Human Genome Sciences, Inc. Albumin fusion proteins
EP1286691B1 (en) * 2000-05-02 2007-11-14 Action Pharma A/S Methods for treatment of diseases associated with acute inflammation under non-ischemic conditions
US20020061849A1 (en) * 2000-05-02 2002-05-23 Soren Nielsen Methods for treatment of diseases associated with inflammation under non-ischemic conditions
US20030072737A1 (en) * 2000-12-29 2003-04-17 Michael Brines Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs
US7767643B2 (en) 2000-12-29 2010-08-03 The Kenneth S. Warren Institute, Inc. Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs
US20020169128A1 (en) * 2001-04-09 2002-11-14 Geroge Sigounas Erythropoietin ameliorates chemotherapy-induced toxicity in vivo
EP1930023A3 (en) * 2001-04-09 2008-08-06 East Carolina University Erythropoietin ameliorates chemotherapy-induced toxicity in vivo
AU2002310122A1 (en) * 2001-05-25 2002-12-09 Human Genome Sciences, Inc. Chemokine beta-1 fusion proteins
EP1459762B1 (en) * 2001-11-02 2008-07-02 Yoshiko Yasuda Use of emp9 for the prevention of proliferative organ diseases
AU2002364586A1 (en) 2001-12-21 2003-07-30 Delta Biotechnology Limited Albumin fusion proteins
GB0211578D0 (en) 2002-05-21 2002-06-26 Univ Belfast Medicaments
DE10234192B4 (de) 2002-07-26 2009-11-26 Epoplus Gmbh Co.Kg Verwendung von Erythropoetin
CA2513213C (en) 2003-01-22 2013-07-30 Human Genome Sciences, Inc. Albumin fusion proteins
KR20070008519A (ko) * 2003-09-29 2007-01-17 워렌 파마슈티칼즈 인코포레이티드 패혈증 및 유착 형성의 치료 및 예방용 조직 보호성사이토카인
EP1686979A4 (en) * 2003-11-07 2010-03-03 Jackson H M Found Military Med ACTIVATION OF HYPOXIA-INDUCIBLE GENE EXPRESSION
DE102004004509B4 (de) * 2004-01-23 2010-07-01 Epoplus Gmbh Co.Kg Einsatz von niedrig dosiertem Erythropoietin zur Stimulation endothelialer Vorläuferzellen sowie zur Organregeneration und Progressionsverlangsamung von Endorganschäden
US20050267027A1 (en) * 2004-04-05 2005-12-01 Lounsbury Karen M Use of erythropoietin for treatment of cancer
US20110076255A1 (en) * 2005-11-07 2011-03-31 Pecora Andrew L Compositions and methods for treating progressive myocardial injury due to a vascular insufficiency
US20080249001A1 (en) * 2006-10-25 2008-10-09 Ajinomoto Co. Inc. Agents that alleviate side-effects caused by chemotherapy agents
RU2426174C1 (ru) * 2010-03-29 2011-08-10 Государственное образовательное учреждение высшего профессионального образования "Курский государственный медицинский университет Федерального агентства по здравоохранению и социальному развитию" Способ фармакологической коррекции ишемии конечности, в том числе при l-name индуцированном дефиците оксида азота
US9533010B2 (en) * 2011-10-31 2017-01-03 Amorcyte, Llc Compositions and methods for treating progressive myocardial injury due to a vascular insufficiency
JP6426693B2 (ja) 2013-03-15 2018-11-21 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 抗ｃｄ４７薬の処理上有効量を達成するための方法
IL308638A (en) * 2021-05-18 2024-01-01 Attias Eyal Use of erythropoietin or a substance that encourages erythropoiesis, to treat osteomyelitis and bone infection

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4745099A (en) * 1985-02-06 1988-05-17 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition for the treatment of the anemia of malignant tumors
US5635160A (en) * 1995-06-07 1997-06-03 The University Of North Carolina At Chapel Hill Dinucleotides useful for the treatment of cystic fibrosis and for hydrating mucus secretions

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6045849B2 (ja) * 1980-08-25 1985-10-12 林原 健 ヒトエリトロポエチンの製造方法
US5002755A (en) * 1988-02-18 1991-03-26 Vanderbilt University Method of controlling nephrotoxicity of anti-tumor plaintum compounds
JP2632014B2 (ja) * 1988-03-03 1997-07-16 中外製薬株式会社 骨髄機能障害性貧血治療剤
US5716644A (en) * 1992-06-11 1998-02-10 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
JPH0782174A (ja) * 1993-09-17 1995-03-28 Takeda Chem Ind Ltd 抗腫瘍剤
US5626862A (en) * 1994-08-02 1997-05-06 Massachusetts Institute Of Technology Controlled local delivery of chemotherapeutic agents for treating solid tumors
EP0802801A2 (en) * 1994-12-30 1997-10-29 Chiron Corporation Methods and compositions for treatment of solid tumors in vivo

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4745099A (en) * 1985-02-06 1988-05-17 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition for the treatment of the anemia of malignant tumors
US5635160A (en) * 1995-06-07 1997-06-03 The University Of North Carolina At Chapel Hill Dinucleotides useful for the treatment of cystic fibrosis and for hydrating mucus secretions

Also Published As

Publication number Publication date
CN1429623A (zh) 2003-07-16
US20020052309A1 (en) 2002-05-02
ES2231889T3 (es) 2005-05-16
ATE282425T1 (de) 2004-12-15
CA2265547A1 (en) 1998-03-19
PT933995E (pt) 2005-02-28
US7531501B1 (en) 2009-05-12
EP0933995A4 (en) 2002-08-28
US20080124401A1 (en) 2008-05-29
EP0933995A1 (en) 1999-08-11
CN1235512A (zh) 1999-11-17
JP2001503028A (ja) 2001-03-06
US5922674A (en) 1999-07-13
CA2265547C (en) 2009-12-01
HK1022810A1 (en) 2000-08-25
JP2009196999A (ja) 2009-09-03
DE69731652T2 (de) 2005-12-15
CN1250281C (zh) 2006-04-12
WO1998010650A1 (en) 1998-03-19
US20090285908A1 (en) 2009-11-19
DK0933995T3 (da) 2005-02-14
DE69731652D1 (de) 2004-12-23
EP0933995B1 (en) 2004-11-17
EP0933995B8 (en) 2005-01-19
JP2008133305A (ja) 2008-06-12
US7803408B2 (en) 2010-09-28

Similar Documents

Publication Publication Date Title
CN1113669C (zh) 治疗内皮创伤的方法
US6689351B1 (en) Use of GM-CSF to promote accelerated wound healing
CN100379446C (zh) 红细胞生成素改善化疗诱导的体内毒性
AU2002256133A1 (en) Erythropoietin ameliorates chemotherapy-induced toxicity in vivo
US20130150649A1 (en) Sensitization of tumor cells to radiation therapy through administration of endothelin agonists
CN1183962C (zh) 具有动员活性的制剂
US8642026B2 (en) Methods and compositions for contributing to the treatment of cancers
JP2009524612A (ja) 多発性硬化症を治療及び／又は予防するための方法、ならびに多発性硬化症の間欠的治療用及び／又は間欠的予防用の薬剤を製造するためのエリスロポエチンの使用
Jaffe et al. Comparison of daily and twice-weekly schedule of L-asparaginase in childhood leukemia
HK1022810B (en) Method of treating endothelial injury
WO2008073653A2 (en) Il- 17b for use in wound healing
Minatoguchi Cytokine Therapy
JP2003342194A (ja) 組織再生剤
KR20070015549A (ko) 에리트로포이에틴의 병용 용량요법
EP1930023A2 (en) Erythropoietin ameliorates chemotherapy-induced toxicity in vivo
MARROW CIRCADIAN STAGE DEPENDENT

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee